81 related articles for article (PubMed ID: 10070326)
1. Anti-HER-2/neu antibodies detected in sera of patients with breast cancer, but also in healthy females.
Jasinska J; Wiltschke C; Brodowicz T; Zielinski CC; Hoffmann-Sommergruber K; Zeillinger R
Eur J Cancer; 1998 Dec; 34(13):2135. PubMed ID: 10070326
[No Abstract] [Full Text] [Related]
2. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.
Disis ML; Pupa SM; Gralow JR; Dittadi R; Menard S; Cheever MA
J Clin Oncol; 1997 Nov; 15(11):3363-7. PubMed ID: 9363867
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu.
Jasinska J; Wagner S; Radauer C; Sedivy R; Brodowicz T; Wiltschke C; Breiteneder H; Pehamberger H; Scheiner O; Wiedermann U; Zielinski CC
Int J Cancer; 2003 Dec; 107(6):976-83. PubMed ID: 14601058
[TBL] [Abstract][Full Text] [Related]
4. Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer.
Ward RL; Hawkins NJ; Coomber D; Disis ML
Hum Immunol; 1999 Jun; 60(6):510-5. PubMed ID: 10408800
[TBL] [Abstract][Full Text] [Related]
5. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.
Disis ML; Calenoff E; McLaughlin G; Murphy AE; Chen W; Groner B; Jeschke M; Lydon N; McGlynn E; Livingston RB
Cancer Res; 1994 Jan; 54(1):16-20. PubMed ID: 7505195
[TBL] [Abstract][Full Text] [Related]
6. Murine monoclonal anti-idiotypic antibody as a surrogate antigen for human Her-2/neu.
Baral R; Sherrat A; Das R; Foon KA; Bhattacharya-Chatterjee M
Int J Cancer; 2001 Apr; 92(1):88-95. PubMed ID: 11279611
[TBL] [Abstract][Full Text] [Related]
7. Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast.
Kuerer HM; Peoples GE; Sahin AA; Murray JL; Singletary SE; Castilleja A; Hunt KK; Gershenson DM; Ioannides CG
J Interferon Cytokine Res; 2002 May; 22(5):583-92. PubMed ID: 12060497
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal and polyclonal humoral immune response to EC HER-2/NEU peptides with low similarity to the host's proteome.
Mittelman A; Lucchese A; Sinha AA; Kanduc D
Int J Cancer; 2002 Apr; 98(5):741-7. PubMed ID: 11920645
[TBL] [Abstract][Full Text] [Related]
9. The significance of anti-sialyl-Tn antibodies in patients with colorectal and breast cancer.
Coomber DW; Hawkins NJ; Dalley D; Ward RL
Neoplasma; 1998; 45(1):12-6. PubMed ID: 9604995
[TBL] [Abstract][Full Text] [Related]
10. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
[TBL] [Abstract][Full Text] [Related]
11. Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro.
Brodowicz T; Wiltschke C; Budinsky AC; Krainer M; Steger GG; Zielinski CC
Int J Cancer; 1997 Dec; 73(6):875-9. PubMed ID: 9399669
[TBL] [Abstract][Full Text] [Related]
12. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
Knutson KL; Schiffman K; Cheever MA; Disis ML
Clin Cancer Res; 2002 May; 8(5):1014-8. PubMed ID: 12006513
[TBL] [Abstract][Full Text] [Related]
13. Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu.
Riemer AB; Klinger M; Wagner S; Bernhaus A; Mazzucchelli L; Pehamberger H; Scheiner O; Zielinski CC; Jensen-Jarolim E
J Immunol; 2004 Jul; 173(1):394-401. PubMed ID: 15210798
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
Rentzsch C; Kayser S; Stumm S; Watermann I; Walter S; Stevanoviç S; Wallwiener D; Gückel B
Clin Cancer Res; 2003 Oct; 9(12):4376-86. PubMed ID: 14555509
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu.
Valone FH; Kaufman PA; Guyre PM; Lewis LD; Memoli V; Ernstoff MS; Wells W; Barth R; Deo Y; Fisher J
J Hematother; 1995 Oct; 4(5):471-5. PubMed ID: 8581387
[TBL] [Abstract][Full Text] [Related]
16. SOX2 autoantibodies as noninvasive serum biomarker for breast carcinoma.
Sun Y; Zhang R; Wang M; Zhang Y; Qi J; Li J
Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):2043-7. PubMed ID: 22832207
[TBL] [Abstract][Full Text] [Related]
17. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract][Full Text] [Related]
18. HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones.
Perez SA; Sotiropoulou PA; Sotiriadou NN; Mamalaki A; Gritzapis AD; Echner H; Voelter W; Pawelec G; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2002 Jan; 50(11):615-24. PubMed ID: 11807625
[TBL] [Abstract][Full Text] [Related]
19. Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients.
Nagorsen D; Scheibenbogen C; Schaller G; Leigh B; Schmittel A; Letsch A; Thiel E; Keilholz U
Int J Cancer; 2003 Jun; 105(2):221-5. PubMed ID: 12673683
[TBL] [Abstract][Full Text] [Related]
20. Tissue expression and serum levels of HER-2/neu in patients with breast cancer.
Krainer M; Brodowicz T; Zeillinger R; Wiltschke C; Scholten C; Seifert M; Kubista E; Zielinski CC
Oncology; 1997; 54(6):475-81. PubMed ID: 9394844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
